1 / 25

Dr Joy Ratcliffe, Consultant Psychiatrist Dr Julie Colville, Clinical Psychologist

Behavioural and Psychological Symptoms of Dementia Non-pharmacological and pharmacological approaches. Dr Joy Ratcliffe, Consultant Psychiatrist Dr Julie Colville, Clinical Psychologist Lorraine Smith, Advanced Practitioner Manchester Mental Health and Social Care Trust & CMFT. BPSD.

ora
Télécharger la présentation

Dr Joy Ratcliffe, Consultant Psychiatrist Dr Julie Colville, Clinical Psychologist

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Behavioural and Psychological Symptoms of Dementia Non-pharmacological and pharmacological approaches Dr Joy Ratcliffe, Consultant Psychiatrist Dr Julie Colville, Clinical Psychologist Lorraine Smith, Advanced Practitioner Manchester Mental Health and Social Care Trust & CMFT

  2. BPSD • What is it? • Heterogeneous group non- cognitive behaviours • Not a diagnostic category – but very important • Think as a list of disturbed behaviours e.g. • Wandering • Agitation • Sexually disinhibited behaviours • Aggression • Paranoia/suspicion • Eliciting psychological/psychiatric problems e.g. depression, anxiety, delusional ideas/psychosis • All adds to risk

  3. BPSD • Behavioural and psychological symptoms of dementia (BPSD) are common • They can be problematic in clinical practice and can form a significant part of the day-to-day work of primary care teams, later life psychiatry teams. CMHTs, inpatient and community settings. • We need to improve recognition and management of BPSD • Improved management can have a positive impact on the quality of life of our patients and carers both at home and in nursing/residential setting s • Positive management may also delay 24hr care

  4. BPSD - Prevalence • Vary widely • Approx 2/3rds will experience BPSD at any one time • Approx 1/3 in the ‘clinically significant ‘range • Can rise to 80% in care homes • 20% for BPSD in Alzheimer’s disease • BPSD tends to fluctuate with psycho-motor agitation most common and persistent

  5. BPSD - Impact • BPSD rather than cognitive features are the major causes of care giving burden • Paranoia, aggression, disturbed sleep-wake cycles important drivers for 24hr care • BPSD also associated with worse outcome and illness progression • Adds significantly to direct and indirect care costs

  6. Multiple Factors that influence Behaviour

  7. Non Pharmacological management of BPSD – • Must be ‘collaborative’ - • Needs thorough Assessment - multiple factors • Need nursing home staff to input into assessment e.g. what do they know about their client? • Need staff e.g. Nursing Home to play key part e.g. ABCs - helps identify factors such as over/under stimulation, pain etc • Need staff to implement and monitor plans • Care Staff do need training in dementia • Need medical staff to ensure physical problems optimally treated e.g. infection, pain

  8. Non Pharmacological management of BPSD • Understanding client’s history, lifestyle, culture and preferences, including their likes, dislikes, hobbies and interests. • Providing opportunities for the person to have conversations with other people. • Ensuring the person has the chance to try new things or take part in activities they enjoy. • Environmental factors-signage, lighting, photographs. • Reminiscence therapy.

  9. Shared Care • Shared care plans to enhance communication and collaboration. • Discuss shared care plan.

  10. Principle of Behaviour Management - Observing and Describing • What is happening • When does it happen • How often does it happen • Who is there when it’s happening • What is communication like • Why do you think it is happening • Any other observations

  11. Principles of Behaviour Management- Contingencies • What are we targeting: • Frequency/ severity • High frequency/ low severity (lower consequences) • Low frequency/high severity (higher consequences) • High frequency/High severity (highest consequences) • What are ‘contingencies? e.g. positive and negative reinforcement

  12. Biological Management • Treat underlying cause • Psychotropics? • Severity • Risk • Distress • Medical comorbidity / other meds esp vascular risks • Capacity • Views carers

  13. Assessment • Delirium (caution not to miss hypoactive)? • PINCH ME (pain, infection, nutrition, constipation, hydration, medications, environment) • PAIN (physical / pain, activity related, iatrogenic, noise / environment)

  14. START LOW GO SLOW • Review target symptoms and adverse effects • How long to treat for • Gradual withdrawal • Licensed?

  15. Psychosis- risperidone (0.25-0.5mg bd), olanzapine (2.5-10mg), quetiapine (25-150mg) amisulpiride, aripiprazole, zuclopethixol • Aggression- as above, trazadone, clomethiazole • Agitation / anxiety- as above, citalopram, mirtazepine, memantine (AD), pregabalin • Depression- sertraline, citalopram, mirtazepine • Mania- valproate, lithium, antipsychotics • Apathy- sertraline, citalopram, cholinesterase inhibitor (D, R, G) • Sleep- temazapam, zopiclone, melantonin

  16. Lewy Body Dementia (LBD) • CAUTION WITH ANTIPSYCHOTICS- quetiapine, aripiprazole, clozapine • 1st choice cholinesterase inhibitors • Clonazepam for REM sleep disorders

  17. Vascular Dementia (VD) • Cholineterase inhibitors and memantine not licensed but majority of cases mixed AD / VD

  18. Cholinesterase Inhibitors • Bradycardia • Prolonged QTC • LBBB • Gastric bleeding risk (pmhx, aspirin, NSAIDS, warfarin) • COPD / asthma • Epilepsy

  19. Antipsychotics • ECG, QTC, other changes • Vascular risks • Increase cognitive impairment

  20. Antidepressants • Sedation • GI bleeding • Na • Falls (inc SSRIs) • Citalopram –QTC, max dose 20mg

  21. Anticonvulsants • Limited evidence • Adverse effects

  22. Case Example • Case example • 75, female, vascular dementia, 24 hr care for 12 months • Complaints from care staff • agitation • ‘breathless’ hyperventilating, • ‘attention seeking’ – calling every 5 mins • Saying pain (but where?) • toileting – incontinent faeces • falls, (needing extra monitoring)

  23. Case Example • PERSONAL – lived alone many years – over stimulated • - remove to quieter environment • DEMENTIA – vascular with periods disorientation unable to express distress (language) • - try and reorientation/reassurance spend time with

  24. Case Example • PHYSICAL – incontinence = ‘overflow’ compacted, meds 2 x laxatives and codeine (opposite actions?), pain (unable to express) • - Elimination of acute physical illness as triggers for BPSD. Reviewed with Advanced Practitioner - GP to check pain and review meds, • FALLS – interaction meds Trazadone and codeine , over –sedated • - meds review, Falls Team, Physio, frame

  25. Case Example • PSYCHOLOGICAL – fear of falling exacerbated by previous falls, highly anxious (premorbidly – calling ambulance, GP, police etc) • Ongoing assessment by Psychology, anxiety still prominent • Linked to disorientation and/or premorbid anxiety • Activity/distraction, optimal? • Co pharmacological treatments – optimally treated?

More Related